Fluconazole: Difference between revisions
From IDWiki
(added breakpoints table) |
(→) |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 10: | Line 10: | ||
*Efficacy predicted by AUC/MIC ratio |
*Efficacy predicted by AUC/MIC ratio |
||
===Clinical Breakpoints=== |
|||
{| class="wikitable" |
{| class="wikitable" |
||
! rowspan="2" |Species |
! rowspan="2" |Species |
||
! rowspan="2" |ECV (μg/mL) |
|||
! colspan="4" |Breakpoints (μg/mL) |
! colspan="4" |Breakpoints (μg/mL) |
||
! colspan="4" |Breakpoints (mm) |
! colspan="4" |Breakpoints (mm) |
||
|- |
|- |
||
!S |
!S |
||
| ⚫ | |||
!SDD |
!SDD |
||
| ⚫ | |||
!R |
!R |
||
!S |
!S |
||
| ⚫ | |||
!SDD |
!SDD |
||
| ⚫ | |||
!R |
!R |
||
|- |
|- |
||
|[[Candida albicans]] |
|[[Candida albicans]] |
||
|0.5 |
|||
|≤2 |
|≤2 |
||
| ⚫ | |||
|4 |
|4 |
||
| ⚫ | |||
|≥8 |
|≥8 |
||
|≥17 |
|≥17 |
||
| ⚫ | |||
|14-16 |
|14-16 |
||
| ⚫ | |||
|≤13 |
|≤13 |
||
| ⚫ | |||
|[[Candida dubliniensis]] |
|||
|0.5 |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Candida glabrata]] |
|[[Candida glabrata]] |
||
|8 |
|||
|— |
|— |
||
| ⚫ | |||
|— |
|— |
||
| ⚫ | |||
|≥64 |
|≥64 |
||
| ⚫ | |||
|— |
|— |
||
|≥15 |
|≥15 |
||
| ⚫ | |||
|≤14 |
|≤14 |
||
|- |
|||
|[[Candida guilliermondii]] |
|||
|8 |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Candida krusei]] |
|[[Candida krusei]] |
||
| |
|||
| colspan="4" |intrinsically resistant |
| colspan="4" |intrinsically resistant |
||
| colspan="4" |intrinsically resistant |
| colspan="4" |intrinsically resistant |
||
|- |
|||
|[[Candida lusitaniae]] |
|||
|1 |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Candida parapsilosis]] |
|[[Candida parapsilosis]] |
||
|1 |
|||
|≤2 |
|≤2 |
||
|4 |
|||
|— |
|— |
||
| ⚫ | |||
|≥8 |
|≥8 |
||
|≥17 |
|≥17 |
||
| ⚫ | |||
|14-16 |
|14-16 |
||
| ⚫ | |||
|≤13 |
|≤13 |
||
|- |
|- |
||
|[[Candida tropicalis]] |
|[[Candida tropicalis]] |
||
|1 |
|||
|≤2 |
|≤2 |
||
| ⚫ | |||
|4 |
|4 |
||
| ⚫ | |||
|≥8 |
|≥8 |
||
|≥17 |
|≥17 |
||
| ⚫ | |||
|14-16 |
|14-16 |
||
| ⚫ | |||
|≤13 |
|≤13 |
||
|- |
|||
|[[Cryptococcus neoformans]] |
|||
|8 |
|||
| colspan="8" rowspan="2" | |
|||
|- |
|||
|[[Cryptococcus gattii]] |
|||
|16-32 |
|||
|} |
|} |
||
== |
== Dosing == |
||
* Invasive candidiasis: fluconazole 6 to 12 mg/kg PO/IV q24h |
|||
*[[Candidemia]]: 12 mg/kg IV load followed by 6 mg/kg PO/IV daily |
|||
**Can use 800 mg daily for isolates that show dose-dependent susceptibility |
|||
*[[Vaginal candidiasis]]: 150 mg PO once, with or without intravaginal [[clotrimazole]] |
|||
*[[Oral thrush]]: 100 mg po daily for 7 to 14 days |
|||
*[[Esophageal candidiasis]]: 200 mg PO daily for 14 to 21 days |
|||
*[[Urinary tract infection]]: 200 mg po daily for 7 to 14 days |
|||
*[[Intra-abdominal infections|Intraabdominal infection]]: 400 mg PO daily |
|||
===Monitoring=== |
|||
*ECG for QT prolongation |
*ECG for QT prolongation |
||
| Line 83: | Line 141: | ||
*Beware [[Adverse drug reaction::drug-drug interactions]], especially with new DOACs |
*Beware [[Adverse drug reaction::drug-drug interactions]], especially with new DOACs |
||
[[Category: |
[[Category:Triazoles]] |
||
Latest revision as of 23:25, 12 November 2021
Background
- Antifungal in the triazole family with excellent bioavadilability but limited efficacy outside of Candida
Pharmacokinetics and Pharmacodynamics
- Good oral bioavailability
- Good CNS penetration
- Fungistatic
- Efficacy predicted by AUC/MIC ratio
Clinical Breakpoints
| Species | ECV (μg/mL) | Breakpoints (μg/mL) | Breakpoints (mm) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| S | SDD | I | R | S | SDD | I | R | ||
| Candida albicans | 0.5 | ≤2 | 4 | — | ≥8 | ≥17 | 14-16 | — | ≤13 |
| Candida dubliniensis | 0.5 | ||||||||
| Candida glabrata | 8 | — | ≤32 | — | ≥64 | — | ≥15 | — | ≤14 |
| Candida guilliermondii | 8 | ||||||||
| Candida krusei | intrinsically resistant | intrinsically resistant | |||||||
| Candida lusitaniae | 1 | ||||||||
| Candida parapsilosis | 1 | ≤2 | 4 | — | ≥8 | ≥17 | 14-16 | — | ≤13 |
| Candida tropicalis | 1 | ≤2 | 4 | — | ≥8 | ≥17 | 14-16 | — | ≤13 |
| Cryptococcus neoformans | 8 | ||||||||
| Cryptococcus gattii | 16-32 | ||||||||
Dosing
- Invasive candidiasis: fluconazole 6 to 12 mg/kg PO/IV q24h
- Candidemia: 12 mg/kg IV load followed by 6 mg/kg PO/IV daily
- Can use 800 mg daily for isolates that show dose-dependent susceptibility
- Vaginal candidiasis: 150 mg PO once, with or without intravaginal clotrimazole
- Oral thrush: 100 mg po daily for 7 to 14 days
- Esophageal candidiasis: 200 mg PO daily for 14 to 21 days
- Urinary tract infection: 200 mg po daily for 7 to 14 days
- Intraabdominal infection: 400 mg PO daily
Monitoring
- ECG for QT prolongation
- Liver enzymes for hepatitis
Adverse Drug Reactions
- Best side effect profiles of the antifungals
- Before starting, check:
- Liver enzymes as baseline (hepatitis)
- Creatinine (requires renal dosing)
- EKG (QTc prolongation)
- Beware drug-drug interactions, especially with new DOACs
